Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-03. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
A recombinant fusion protein is a protein created through genetic engineering of a fusion gene. This typically involves removing the stop codon from a cDNA sequence coding for the first protein, then appending the cDNA sequence of the second protein in frame through ligation or overlap extension PCR. That DNA sequence will then be expressed by a cell as a single protein. The protein can be engineered to include the full sequence of both original proteins, or only a portion of either. If the two entities are proteins, often linker (or "spacer") peptides are also added, which make it more likely that the proteins fold independently and behave as expected. Especially in the case where the linkers enable protein purification, linkers in protein or peptide fusions are sometimes engineered with cleavage sites for proteases or chemical agents that enable the liberation of the two separate proteins. This technique is often used for identification and purification of proteins, by fusing a GST protein, FLAG peptide, or a hexa-his peptide (6xHis-tag), which can be isolated using affinity chromatography with nickel or cobalt resins. Di- or multimeric chimeric proteins can be manufactured through genetic engineering by fusion to the original proteins of peptide domains that induce artificial protein di- or multimerization (e.g., streptavidin or leucine zippers). Fusion proteins can also be manufactured with toxins or antibodies attached to them in order to study disease development.
=== Mammals === Several groups of ungulates have independently reduced or lost side digits on their feet, often leaving one or two digits for walking. That name comes from their hooves, which have evolved from claws several times. For example, horses have one walking digit and domestic bovines two on each foot. Various other land vertebrates have also reduced or lost digits. Similarly, laurasiathere perissodactyls and afrothere paenungulates have several features in common, to the point of there being no obvious distinction among basal taxa of both groups. Many aquatic mammals or marine mammals independently came to have adaptations to live in water, such as similar-looking tail flukes in dugongs and whales. Unrelated herbivores and carnivores have adapted to marine and freshwater environments. The flipper forelimbs of marine mammals (cetaceans, pinnipeds, and sirenians) are a classic example of convergent evolution. There is widespread convergence at the gene level. Distinct substitutions in common genes created various aquatic adaptations, most of which also constitute parallel evolution because the substitutions in question are not unique to those animals. The pronghorn of North America, while not a true antelope and only distantly related to them, closely resembles the true antelopes of the Old World, both behaviorally and morphologically. It also fills a similar ecological niche and is found in the same biomes. Members of the two clades Australosphenida and Theria evolved tribosphenic molars independently.
=== August === 1 August – Stella Maris, the Rector of the University of St Andrews, is removed from the university's governing body over a letter she sent to students shortly after taking office in which she called for an immediate ceasefire in Gaza and referred to "genocidal attacks" made by the Israeli government. She will remain as Rector until October 2026, when her term ends. 4 August – A yellow weather warning is issued for heavy rain and strong winds in parts of Scotland, which is active until 9pm the following day. 6 August – Fiona Robertson, the chief executive of the Scottish Qualifications Authority, apologises after around 7,000 students who took their Higher examinations received blank emails instead of their results. The results were later sent by text message. 8 August – Cosla puts forward a new offer of a 3.6% increase for all grades of refuse workers in a bid to prevent strikes in 26 of Scotland's 32 council areas. The offer would represent a rise of £1,292 for the lowest paid, equivalent to a 5.63% increase. 8–12 August – The 82nd World Science Fiction Convention takes place in Glasgow. 9 August – 2024 United Kingdom riots: Police Scotland announces it is sending 120 of their officers to Belfast to help deal with ongoing riots in the city. 12 August – Unison, Unite and the GMB suspend planned strikes by refuse collectors following a new offer from Cosla. 13 August – Scotland's gender service for young people, based in Glasgow, announces it will stop accepting self-referrals.
Sources: en.wikipedia.org
Counter-Strike – A team-based tactical first-person shooter game involving rounds of combat between two teams, counter-terrorists and terrorists. Counter-Strike was later released commercially by Valve as a standalone game. Day of Defeat – A World War II first-person shooter, originally a mod and later a commercially released game. Deathmatch Classic – An official mod by Valve that updates the multiplayer gameplay from id Software's Quake, featuring enhanced textures, models, and lighting. It was released on June 7, 2001, and included in an update to Half-Life a month later. OS X and Linux ports of the Windows game were released through Steam in August 2013. Deathmatch Plus – A mod split off from Oz Deathmatch. The mod has a "Lights Out" mode that turns off all the bright lights in a map. Also includes night vision goggles, a silenced machine gun and hand grenades can be exchanged for cluster bombs. CNET Gamecenter placed it on its list of top 10 Half-Life mods, comparing it to Oz Deathmatch, saying that the mod is easier to use and the grappling hook is better but the night vision mode is worse. Earth's Special Forces – Third-person fighting oriented game based on the anime Dragon Ball Z. In development since at least 2000, when early alpha versions were released, the mod features fast-paced 3D melee combat, shooting energy attacks, flight mechanics, character transformations, and multiple game modes. Each playable character has unique abilities, along with distinct strengths and weaknesses.
=== Genes in other plants === CLE genes have been found in numerous monocots, dicots, and even moss. Research has even shown that some plants, like rice, contain the presence of a multi-CLE domain. Various CLE-like genes have also been found in the genomes of plant-parasitic nematodes such as beet, soybean and potato cyst nematodes.
Temperature in the anus (rectum/rectal) is at or over 37.5–38.3 °C (99.5–100.9 °F). An ear (tympanic) or forehead (temporal) temperature may also be used. Temperature in the mouth (oral) is at or over 37.2 °C (99.0 °F) in the morning or over 37.7 °C (99.9 °F) in the afternoon Temperature under the arm (axillary) is usually about 0.6 °C (1.1 °F) below core body temperature. In adults, the normal range of temperatures in healthy individuals is 36.32–37.76 °C (97.4–100.0 °F) (rectal), 35.76–37.52 °C (96.4–99.5 °F) (ear), 35.61–37.61 °C (96.1–99.7 °F) (urine), 35.73–37.41 °C (96.3–99.3 °F) (oral), and 35.01–36.93 °C (95.0–98.5 °F) (axillary), with no significant gender differences. Normal body temperatures vary depending on many factors, including age, sex, time of day, ambient temperature, activity level, and more. Normal daily temperature variation has been described as 0.5 °C (0.9 °F). A raised temperature is not always a fever. For example, the temperature rises in healthy people when they exercise, but this is not considered a fever, as the set point is normal. On the other hand, a "normal" temperature may be a fever, if it is unusually high for that person; for example, medically frail elderly people have a decreased ability to generate body heat, so a "normal" temperature of 37.3 °C (99.1 °F) may represent a clinically significant fever.
STRIDE: A Microsoft model that identifies threats across six categories: spoofing, tampering, repudiation, information disclosure, denial of service, and elevation of privilege. MITRE ATLAS: A knowledge base of adversary tactics and techniques for AI systems. OWASP GenAI Security Project: Provides guidance on vulnerabilities associated with generative AI and large language model integration, including guidelines specifically for agentic applications. MAESTRO: A framework from the Cloud Security Alliance for assessing risks in AI systems throughout their lifecycle.
Sources: en.wikipedia.org
Strontium-90 (90Sr) is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 28.91 years. It undergoes β− decay into 90Y (yttrium-90) with a decay energy of 546 keV. 90Sr has applications in medicine and industry and is an isotope of concern in fallout from nuclear weapons, nuclear weapons testing, and nuclear accidents.
Juan Zarate, who served as Deputy National Security Advisor for Combating Terrorism from 2005 to 2009, noted that "the severity and extreme disruption of a novel coronavirus will likely spur the imagination of the most creative and dangerous groups and individuals to reconsider bioterrorist attacks."
John Kampfner, author, broadcaster and commentator; executive director at Chatham House; has written and presented for Reuters, The Daily Telegraph; chief political correspondent at the Financial Times; political commentator for BBC's Today radio programme; political correspondent on Newsnight; was chair of the Clore Duffield Foundation, Council of King's College London; Chief Executive of the freedom of expression organisation Index on Censorship and established Creative Industries Federation; shortlisted for the Orwell Book prize. Efraim Karsh (born 6 September 1953) British-Israeli historian at King's College London; director of political studies Bar-Ilan University the Begin-Sadat Center for Strategic Studies).; former director of Middle East Forum; held posts at Harvard, Columbia universities, Sorbonne, London School of Economics, Helsinki University, International Institute for Strategic Studies, Kennan Institute for Advanced Russian Studies in Washington D.C., and Jaffee Center for Strategic Studies at Tel Aviv University; in 1989 joined King's College London; has contributed articles to The New York Times, The Los Angeles Times, The Wall Street Journal, The Times (London) and The Daily Telegraph. His book Palestine Betrayed argued that 1948 Palestinian expulsion and flight was "exclusively of their own making".
Translational Research: The Journal of Laboratory and Clinical Medicine is a monthly peer-reviewed medical journal covering translational research. It was established in 1915 as The Journal of Laboratory and Clinical Medicine obtaining its current title in 2006. Jeffrey Laurence (Weill Cornell Medical College) has been editor-in-chief since 2006. He was preceded by Dale Hammerschmidt. It is the official journal of the Central Society for Clinical and Translational Research. It is published by Mosby.
Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979 and binds predominantly to the somatostatin receptors SSTR2 and SSTR5. It was approved for use in the United States in 1988. Octreotide was approved for medical use in the European Union in 2022. As of June 2020, octreotide is the first oral somatostatin analog (SSA) approved by the FDA. It is on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.